ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 4

Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

, , ,

Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
    EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
    EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
    Now Viewing
    EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
    EP. 5: Exciting Data and Trials in Progress from ASCO 2024
    EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
    EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
    EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
    EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
    EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
    EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
    EP. 12: The Role of Chemotherapy in nccRCC Treatment
    EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
    EP. 14: Final Thoughts/Looking Forward
    1. Briefly comment on the COSMIC-313 nivo + ipi +/- cabo study in intermediate/high-risk patients subgroup analysis (Powles, et al. ASCO GU 2023: Abstract 605)
    2. Dr Voss takes time to highlight the LITESPARK-024 trial = belzutifan + palbo > – (McDermott D, et al. ASCO 2023. Abstract TPS4603)
    x